We are proud to be acting as Cayman Islands counsel to AnHeart Therapeutics, a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, during its merger with Nuvation Bio. Immediately following the closing of the acquisition, the former shareholders of AnHeart will own approximately 33% and the current stockholders of Nuvation Bio will own approximately 67% of Nuvation Bio on a fully diluted basis.

This acquisition is excepted to close in the second quarter of 2024.

The Walkers team is being led by Cayman Islands based Corporate partner, Hugh Anderson; Corporate senior counsel, Michael Beck; and Corporate associate Samuel Buchan. Davis Polk & Wardwell LLP is acting as lead U.S legal counsel.